Dr. Ryan Gentzler
Dr. Ryan Gentzler is a thoracic oncologist at the University of Virginia Cancer Center and assistant professor. Dr. Gentzler’s has a clinical focus on the treatment of patients with lung cancer and other thoracic malignancies, including mesothelima. He also has experience treating esophageal cancer and cancers of the head and neck.
Dr. Gentzler has authored and co-authored over a dozen medical studies. His research is centered around the development of novel therapies for lung cancer, with a focus on immunotherapy drugs. He serves as the principle investigator on several clinical trials, and actively works to develop and add new clinical trials for patients in the area to provide access to more promising emerging treatments.
Main Specialty: Hematology, Oncology
Other Interests & Specialties: General oncology, hematologic oncology, lung cancer and other thoracic malignancies, esophageal cancers, head and neck cancers and immune-based therapies.
Certifications, Awards & Accolades: American Board of Internal Medicine Certifications in Internal Medicine and Medical Oncology, Emmanuel M. Weinberger Award for Outstanding Achievement in Hematology/Oncology, Kowlessar Award, Excellence in Teaching Award, Compassionate Care Award
Education & Experience:
- Medical Degree from the Temple University School of Medicine
- Residency for Internal Medicine at Thomas Jefferson University
- Fellowship for Hematology and Oncology at McGaw Medical Center of Northwestern University
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. January 2019;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1. American Journal of Surgical Pathology. September 2018;42(9):1216-1223. doi: 10.1097/PAS.0000000000001099
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncology. November 2016;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3